TCM Biotech International Corp. (TPE:4169)

Taiwan · Delayed Price · Currency is TWD

149.00

+0.50 (0.34%)

Aug 19, 2026, 1:30 PM CST

73.86% (1Y)

Market Cap	8.77B +74.7%
Revenue (ttm)	701.63M +4.0%
Net Income	-31.50M
EPS	-0.52
Shares Out	59.05M
PE Ratio	n/a
Forward PE	111.24
Dividend	0.36 (0.24%)
Ex-Dividend Date	Jul 20, 2026

Volume	63,171
Open	148.00
Previous Close	148.50
Day's Range	148.00 - 150.50
52-Week Range	83.50 - 290.00
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 4169

Full Company Profile

Financial Performance

In 2025, TCM Biotech International's revenue was 685.49 million, an increase of 2.84% compared to the previous year's 666.53 million. Earnings were 19.17 million, a decrease of -8.76%.

Financial Statements